ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.

  title={ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.},
  author={Michal Ugarenko and Abraham Nudelman and Ada Rephaeli and Ken-Ichi Kimura and Don R. Phillips and Suzanne M. Cutts},
  journal={Biochemical pharmacology},
  volume={79 3},
Doxorubicin is an anthracycline anticancer agent that functions primarily by inhibiting topoisomerase II, but also forms covalent DNA adducts depending on the cellular availability of formaldehyde. The combination of formaldehyde-releasing prodrugs (such as AN-9) with doxorubicin has been shown to result in synergistic doxorubicin-DNA adduct formation and synergistic apoptosis in HL-60 leukemic cells, offering the potential for lower concentrations of doxorubicin to be used clinically in order… CONTINUE READING
10 Citations
56 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 10 extracted citations


Publications referenced by this paper.
Showing 1-10 of 56 references

Similar Papers

Loading similar papers…